By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PrognosDx Health today announced a deal with Accium BioScience to develop and commercialize tests based on histone biomarkers.

Palo Alto, Calif.-based PrognosDx will lend its expertise and epigenetic platform technology to the partnership, while Accium, headquartered in Seattle, will contribute its accelerator mass spectrometry platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.